Loading…
Lobbying Spend
—
Filings
7
Firms Hired
1
Active Period
2021–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Ending the Diagnostic Odyssey Act of 2021
2022 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance. S. 4348 - Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2022
S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance. S. 4348 - Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 4348
Ending the Diagnostic Odyssey Act of 2021
2022 · second_quarter · Firm: MEHLMAN CONSULTING, INC.
S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance. S. 4348 - Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2022
S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance. S. 4348 - Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 4348
Ending the Diagnostic Odyssey Act of 2021
2022 · first_quarter · Firm: MEHLMAN CONSULTING, INC.
S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance.
Client expense: — · Firm income: $50,000
Matched citations: S. 2022
Ending the Diagnostic Odyssey Act of 2021
2021 · fourth_quarter · Firm: MEHLMAN CONSULTING, INC.
S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance.
Client expense: — · Firm income: $50,000
Matched citations: S. 2022
Ending the Diagnostic Odyssey Act of 2021
2021 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
S. 2022, The "Diagnostic Odyssey Act" and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance.
Client expense: — · Firm income: $50,000
Matched citations: S. 2022
Ending the Diagnostic Odyssey Act of 2021
2021 · second_quarter · Firm: MEHLMAN CONSULTING, INC.
S. 2022, The "Diagnostic Odyssey Act" and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance.
Client expense: — · Firm income: $20,000
Matched citations: S. 2022
Source: Senate LDA